RTS 28 Quality of Execution Annual Report

Firm: Brevan Howard Asset Management LLP ("BHAM" or the "Firm")
Calendar Year Disclosure Period: 1 January 2017 to 31 December 2017

Date: 30 April 2018

Summary of classes of instruments included in this report, and class of instruments not included in this report (because the Firm has not executed client orders in that class of instruments):

Classes of instruments included in this report	Classes of instruments not included in this report
Debt instruments	Equities Debt Instruments Money market instruments Structured finance instruments Structured finance instruments Supply Derivatives Swaps, forwards and other interest rates derivatives Swaps, forwards and other interest rates derivatives Swaps, forwards and other interest rates derivatives Securitised derivatives Securitised derivatives Contracts for differences Exchange traded products Emission allowances Other instruments

General

BHAM is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") as an Alternative Investment Fund Manager ("AIFM") under the EU Alternative Investment Fund Managers Directive ("AIFMD"). BHAM acts as the AIFM for a non-EU domiciled Alternative Investment Fund ("AIF") and as investment manager for a number of non-EU domiciled Alternative Investment Funds ("AIFs") that are managed by Brevan Howard Capital Management Limited in its capacity as a non-EU based AIFM. The Firm also has certain additional 'top-up' regulatory permissions under the Markets in Financial Instruments Directive and Regulation (together "MiFID II"), in order to carry out portfolio management activities on behalf of UCITS funds and the aforementioned AIFs.

MiFID II imposes a regulatory obligation upon BHAM, as an FCA authorised AIFM, to publish, on an annual basis, a report summarising specific information relating to the execution obtained for each relevant financial instrument traded during the previous year. This information includes disclosure relating to trading volumes with the top five counterparties expressed as a percentage of BHAM's total execution volume and a percentage of the number of executed orders in relation to each relevant class of financial instrument, this is quantitative element contained within the report below. In addition to the quantitative element, BHAM is also required to provide a qualitative report summarising the conclusions drawn from its monitoring of the quality of execution.

For the avoidance of doubt, BHAM's quantitative and qualitative disclosure report below only provides data on BHAM's MIFID II 'top-up' permission activity, in respect of indirect execution, including using a broker's Direct Electronic Access ("DEA") system to access a trading venue; they do not include any transaction activity where BHAM traded directly with its counterparties or where it acted as AIFM for its non-EU AIF. As this is a BHAM disclosure report, activity undertaken by any other investment management entities within the wider Brevan Howard group is not included within this report.

Debt instruments - Bonds

	Debt modulients Bonds	,					
	LB	Venue	Percent	Percent	Percent	Percent	Percent
			Of	Of Order	Of Passive	Of Aggressive	Of Directed
			Volume	Count	Orders	Orders	Orders
1	549300LGG2RLWD21SU97	Amherst Pierpont Securities LLC	34.69	16.82	N/A	N/A	0
2	5493006BWPDUCYG6EQ34	ED & F Man Capital Markets Inc	28.78	14.12	N/A	N/A	0
3	5493003O0P1GJ0O8CI80	Industrial and Commercial Bank of China Financial Services LLC	23.43	7.06	N/A	N/A	0
4	2549004IPXPSM9EJFC92	Mischler Financial Group Inc	5.15	4.47	N/A	N/A	0
5	ZE2ZWJ5BTIQJ8M0C6K34	RBS Securities Inc	2.19	1.06	N/A	N/A	0

Interest rate derivatives - Futures and options admitted to trading on a trading venue

LB	Venue	Percent	Percent	Percent	Percent	Percent
		Of			Of Aggressive	
		Volume	Count	Orders	Orders	Orders
1 XKZZ2JZF41MRHTR1V493	Citigroup Global Markets Limited	31.98	6.5	N/A	N/A	0
2 2138004RRDC64K7UD291	Sigma Broking Limited	14.96	2.92	N/A	N/A	0
3 549300WYFIFDMB6POR04	JB DRAX Honore (UK) Ltd	7.67	11.91	N/A	N/A	0
4 REYPIEJN7XZHSUI0N355	UBS Limited	6.91	5.11	N/A	N/A	0
5 ZWNFQ48RUL8VJZ2AIC12	BGC Brokers LP	6.18	4.87	N/A	N/A	0

Interest rate derivatives - Swaps, forwards, and other interest rates derivatives

	LB	Venue	Percent Of		Percent Of Passive	Percent Of Aggressive	Percent Of Directed
			Volume	Count	Orders	Orders	Orders
1	549300WYFIFDMB6POR04	JB DRAX Honore (UK) Ltd	97.5	95.24	N/A	N/A	0
2	4ZHCHI4KYZG2WVRT8631	Macquarie Bank Limited	2.43	1.9	N/A	N/A	0
3	549300ACVHHYSDIK2029	Archr LLP	0.07	2.86	N/A	N/A	0
4							
5							

Currency derivatives - Futures and options admitted to trading on a trading venue

	LB	Venue	Percent	Percent	Percent	Percent	Percent
			Of	Of Order	Of Passive	Of Aggressive	Of Directed
			Volume	Count	Orders	Orders	Orders
1	1V8Y6QCX6YMJ2OELII46	Credit Suisse Securities (USA) LLC	76.45	89.22	N/A	N/A	0
2	DL6FFRRLF74S01HE2M14	Credit Suisse Securities Europe Limited	23.34	10	N/A	N/A	0
3	DL6FFRRLF74S01HE2M14	Credit Suisse Securities Europe Limited	0.2	0.78	N/A	N/A	0
4							
5							

Currency derivatives - Swaps, forwards, and other currency derivatives

	LB	Venue	Percent	Percent	Percent	Percent	Percent
			Of	Of Order	Of Passive	Of Aggressive	Of Directed
			Volume	Count	Orders	Orders	Orders
1	549300WYFIFDMB6POR04	JB DRAX Honore (UK) Ltd	50.06	36.91	N/A	N/A	0
2	549300BM V W85YF9FGN67	Tullett Prebon (Securities) Limited	27.19	16.36	N/A	N/A	0
3	O26QTPAJC1X7058KCW11	Jefferies Bache Financial Services Inc	8.68	6.93	N/A	N/A	0
4	KX1WK48MPD4Y2NCUIZ63	Natixis S.A.	3.9	7.09	N/A	N/A	0
5	549300BMVW85YF9FGN67	Tullett Prebon (Securities) Limited	3.81	2.26	N/A	N/A	0

Equity Derivatives - Futures and options admitted to trading on a trading venue

LB	Venue	Percent Of Volume	Percent Of Order Count	Percent Of Passive Orders	Percent Of Aggressive Orders	Percent Of Directed Orders
1 1V8Y6QCX6YMJ2OELII46	Credit Suisse Securities (USA) LLC	18.8	13.04	N/A	N/A	0
2 DL6FFRRLF74S01HE2M14	Credit Suisse Securities Europe Limited	12.93	32.76	N/A	N/A	0
3 549300WYFIFDMB6POR04	JB DRAX Honore (UK) Ltd	9.78	1.49	N/A	N/A	0
4 O2RNE8IBXP4R0TD8PU41	Societe Generale S.A.	9.42	1.39	N/A	N/A	0
5 G5GSEF7VJP5I7OUK5573	Barclays Bank PLC	7.85	0.4	N/A	N/A	0

Commodity derivatives and emission allowance derivatives - Futures and options admitted to trading on a trading venue

	Commodity derivatives and emission anowance derivatives in diales and options dufinited to adding on a adding vende						
	LB	Venue	Percent	Percent	Percent	Percent	Percent
			Of	Of Order	Of Passive	Of Aggressive	Of Directed
			Volume	Count	Orders	Orders	Orders
1	R0MUWSFPU8MPRO8K5P83	BNP Paribas - Paris	27.48	4.17	N/A	N/A	0
2	K6Q0W1PS1L1O4IQL9C32	JP Morgan Securities plc	22.55	4.48	N/A	N/A	0
3	W22LROWP2IHZNBB6K528	Goldman Sachs Intl	18.28	3.46	N/A	N/A	0
4	DL6FFRRLF74S01HE2M14	Credit Suisse Securities Europe Limited	17.07	84.99	N/A	N/A	0
5	XKZZ2JZF41MRHTR1V493	Citigroup Global Markets Limited	7.67	1.58	N/A	N/A	0

Class of instrument	Debt Instruments – Bonds Interest rate derivatives – futures and options admitted to trading on a trading venue Interest rate derivatives – swaps, forwards and other interest rate derivatives Currency Derivatives – Futures and options admitted to trading on a trading venue Currency Derivatives – Swaps, forwards and other currency derivatives Equity Derivatives – Futures and options admitted to trading on a trading venue Commodity Derivatives – futures and options admitted to trading on a trading venue					
General observations	·	When making and executing investment decision, BH traders are required to act in good faith and in the best interests of their clients, the funds. With respect to execution, this is achieved by taking all sufficient steps, as required under the FCA rules, to obtain the best possible result for the clients, taking into account the relative important of the execution factors outlined below.				
	identified during the reporting period. No single counterparty is favoured conconsistently provides a superior service, which would include, for example, provide	BHAM monitors the effectiveness of its order execution arrangements to identify and, where necessary, corrects any deficiencies. There were no deficiencies identified during the reporting period. No single counterparty is favoured compared to others, unless it can be demonstrated that such a counterparty consistently provides a superior service, which would include, for example, providing better pricing, liquidity or speed of execution than its competitors. There were no material changes to BHAM's execution arrangements during the reporting period.				
	Summary of analysis	Conclusion				
Execution factors	A number of execution factors may be considered depending on the transaction and the market in question. These may include: 1) Price;	During the period under review, BHAM's overarching execution process was based on these execution factors and criteria as detailed in the Firm's Order Execution Policy.				
	2) Speed;	When effecting transactions on behalf of clients, BHAM will generally				

Close links, conflicts of interest and common ownership with respect to execution venues	 3) Likelihood of execution and settlement; 4) Costs; 5) Size and nature of the order; and 6) Any other consideration relevant to the order. The relative importance of the execution factors detailed above was determined by the following execution criteria: the characteristics of the Client, including the categorisation of the Client as professional; the characteristics of the Client order, including where the order involves a securities financing transaction ("SFT"); the characteristics of the financial instrument that are the subject of that order; and the characteristics of the brokers and/or execution venues to which that order can be directed. Close links The Firm has no close links to report. Conflicts of interest	weight execution factors in an order of priority based on the asset class in question and the prevailing market conditions, all of which may be subject to changes depending on the execution criteria at the time of the transaction. Ordinarily, price will merit a high relative importance in obtaining the best possible result. However, BHAM may, in its absolute discretion, decide that any other factor or factors are or may be more important than price in determining the best possible execution result. This is particularly the case in less liquid or OTC markets. The relative importance given to these execution factors was in line with BHAM's order execution policy and consistent with BHAM's process in respect of these classes of financial instruments. Close links N/A Conflicts of interest
	The Firm has no conflicts of interest to report.	N/A
	Common ownerships The Firm has no common ownership to report.	Common ownerships N/A
Specific arrangements with execution venues regarding payments made or received, discounts, rebates or non-monetary benefits received	Certain Brevan Howard funds have purchased memberships on certain commodity and derivatives exchanges. Such memberships may entitle the member to reduced commission rates in connection with transactions effected on such exchanges, any reduced commission rates are to the benefit of the relevant fund. Brevan Howard has negotiated volume discounts with certain counterparties, any volume discounts that have been negotiated are to the benefit of the relevant funds and never to the Firm.	The Firm followed its inducements procedures in line with its regulatory obligations in relation to these arrangements. In addition, these arrangements did not influence the Firm's selection of those execution venue(s)/broker(s), as the Firm followed its order execution policy and conflicts of interest policy when selecting those execution venues/brokers. As specified previously, all discounts or reduced commission rates are to the benefit of the relevant funds and never to the Firm.
Factors leading to a change in the list of execution venues listed in the order execution policy	There were no significant changes to the list of execution venues in the Firm's Order Execution Policy.	N/A
Differentiation across client categories	N/A - all of the Firm's clients are professional clients	N/A
Use of data / tools relating to quality of execution	During 2017, the Firm did not use any third party data and/or tools relating to quality of execution during the relevant period. The Firm has implemented a third party TCA tool following the implementation of MiFID II in January 2018.	N/A
Use of consolidated tape provider output	The Firm has not used output from consolidated tape providers.	N/A